Ipamorelin dosage: reported doses and schedule
An experimental peptide that triggers growth hormone release.
Also called: NNC 26-0161, NNC-26-0161.
Growth hormone secretagogues (ghrelin receptor) · Ghrelin receptor agonist and growth hormone secretagogue.
Typical reported dose: 100–200 mcg at bedtime, often with CJC no DAC
- IV PK: about 3 mcg/kg: 4.21 nmol/kg IV over 15 minutes; no titration. once in a single-dose cohort, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
- IV PK: about 10 mcg/kg: 14.02 nmol/kg IV over 15 minutes; no titration. once in a single-dose cohort, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
- IV PK: about 30 mcg/kg: 42.13 nmol/kg IV over 15 minutes; no titration. once in a single-dose cohort, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
- IV PK: about 60 mcg/kg: 84.27 nmol/kg IV over 15 minutes; no titration. once in a single-dose cohort, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
- IV PK: about 100 mcg/kg: 140.45 nmol/kg IV over 15 minutes; no titration. once in a single-dose cohort, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
- Bowel surgery: IV twice daily: 0.03 mg/kg IV twice daily on postoperative days 1-7, or until discharge. twice daily, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to Ipamorelin
- MK-677 (ibutamoren): This experimental oral drug raises growth hormone and IGF-1; risks include high blood sugar and swelling.
- GHRP-2: A peptide that releases growth hormone and can increase hunger.
- GHRP-6: A peptide studied in growth hormone tests and an experimental stroke combination.
- Hexarelin: A peptide that releases growth hormone; repeated use can weaken the response.
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Find product information about medicines, Medicines and Healthcare products Regulatory Agency · MHRA · 2026
- Peptide products, Therapeutic Goods Administration · TGA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- GENOTROPIN® (somatropin) for injection, for subcutaneous use, FDA · 2025
- 注射用GHRP科研100, PMDA · 2025
- October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee, FDA · 2024
- October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee, FDA · 2024
- October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting, FDA · 2024
- Using intramuscular injections in people on oral anticoagulants, NHS Specialist Pharmacy Service · NHS Specialist Pharmacy Service · 2023
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.